COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00606801
Recruitment Status : Completed
First Posted : February 5, 2008
Results First Posted : July 31, 2013
Last Update Posted : July 31, 2013
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mehmet Sofuoglu, Yale University

Brief Summary:
To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, a medication approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both of these effects may result in improved cognitive performance in a group of subjects known to have impaired performance in various cognitive tasks.

Condition or disease Intervention/treatment Phase
Cocaine Abuse Drug: Galantamine Drug: placebo Not Applicable

Detailed Description:

Galantamine, compared to placebo, will improve cognitive performance in abstinent cocaine users. The cognitive performance will be measured with the Stroop test and 3 Cambridge Neuropsychological Test Automated Battery (CANTAB) tests: Paired Associate Learning (PAL), Delayed Pattern Recognition Memory (PRM),and Rapid Visual Information Processing (RVIP). Performance on these tests has been shown to be impaired in abstinent cocaine users, compared to healthy controls.

Galantamine, compared to placebo, will not be associated with any significant changes in mood. Monitoring of mood will be achieved with 3 mood scales: 1) Center for Epidemiologic Studies Depression (CES-D) scale, Positive and Negative Affect Schedule (PANAS) and the Profile of Mood States (POMS).

Currently this study is completed, Patients are no longer being enrolled. There were 28 completers. This study has been published.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
Study Start Date : June 2007
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Galantamine 8 mg/day
Galantamine 8 mg/day
Drug: Galantamine
Galantamine 8 mg/day
Other Names:
  • Nivalin,
  • Razadyne,
  • Razadyne ER,
  • Reminyl,
  • Lycoremine

Placebo Comparator: Placebo
Drug: placebo
sugar pill
Other Name: Sugar Pill

Primary Outcome Measures :
  1. Performance on 3 Cognitive Tests From the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP, PAL and PRM. [ Time Frame: Baseline, Day 5 and Day 10 ]
    Rapid Visual Processing test (RVIP) is a measure of sustained attention with a small working memory component that is sensitive to cholinergic enhancers. In the RVIP, subjects must detect either odd or even 3 digit sequences appearing in a box in a pseudo-random order at 100 digits per minute. Reaction time (RT) to correct answers, total hits, correct rejections and A' (sensitivity to target sequences) were determined. Paired Associate Learning (PAL) measures visual memory and new learning by testing a the ability to remember the initial location of a pattern after it is re-presented in the middle of the screen. Errors result in a reminder presentation of the original location. The stages completed and number of errors are measures of interest. Pattern Recognition Memory (PRM) tests visual pattern recognition memory in a two choice forced discrimination paradigm. 12 visual patterns are presented, then the subject must choose between each of these patterns and a novel pattern.

Secondary Outcome Measures :
  1. Performance on the Sustained Attention to Response Task (SART). [ Time Frame: Baseline, Day 5 and Day 10 ]

    The SART is a Go / NoGo task measuring the ability to activate or inhibit responses. Cocaine users are know to have deficits in response inhibition on such tasks. The number of errors on NoGo and Go trials, as well as the mean reaction time (RT in milliseconds) for correct responses on Go Trials were measured.

    Complete data for 3 subjects in the Placebo group, and for 1 subject in the galantamine group were not capture do to experimenter and computer errors.

  2. Performance on the Modified Stroop Task (Cocaine-Stroop) [ Time Frame: Baseline, Day 5 and Day 10 ]
    The Cocaine-Stroop task measures attention capture (attentional bias) secondary to cocaine cues; (Stroop effect - calculated as the difference between mean RT on cocaine words and mean RT on control words). Subjects completed 2 counterbalanced blocks (150 trials per block). One block contained 15 cocaine words and neutral words in a mixed order. The other block contained 15 control words matched in length and frequency to cocaine words, and a different set of neutral words. Subjects were required to indicate the colors in which the words were written as quickly and accurately as possible. Reaction times for identification of word color was measured. In addition, the difference in RT to words following cocaine and control words were measured (carry-over effect). Complete data for 3 participants (2 placebo and 1 galantamine) were not capture due to experimenter and computer errors.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and females, between the ages 21 and 50
  • Fulfill criteria for past cocaine dependence
  • No cocaine use for the past 30 days
  • No other current dependence or abuse of other drugs or alcohol
  • No current medical problems and normal ECG
  • Not pregnant,nor breast feeding,
  • Using acceptable birth control methods.

Exclusion Criteria:

  • Current major psychiatric illness including mood, psychotic or anxiety disorders
  • History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances
  • Use of other medications including,drugs that slow heart rate
  • Known allergy to galantamine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00606801

Layout table for location information
United States, Connecticut
Veterans Affairs Hospital
West Haven, Connecticut, United States, 06516
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D. Yale University Associate Professor
Layout table for additonal information
Responsible Party: Mehmet Sofuoglu, Principle Investigator, Yale University Identifier: NCT00606801    
Other Study ID Numbers: HIC # 0706002768
P50DA009241 ( U.S. NIH Grant/Contract )
B Rounsaville ( Other Identifier: Principal Investigator of P50 grant )
First Posted: February 5, 2008    Key Record Dates
Results First Posted: July 31, 2013
Last Update Posted: July 31, 2013
Last Verified: February 2012
Keywords provided by Mehmet Sofuoglu, Yale University:
cognitive enhancers
Nootropic Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Nootropic Agents